Home » Topics » Regulatory » EMA

EMA
RSS

OBI-1 obtains positive opinion for orphan drug status in Europe

June 18, 2010

EMA approves update to bortezomib label for multiple myeloma

June 17, 2010

COMP recommends orphan drug status for 2B3-101 in glioma

June 16, 2010

EMA's COMP recommends orphan status for DR Cysteamine in cystinosis

June 16, 2010

European Commission extends indication of RoActemra

June 10, 2010

Sunesis receives scientific advice from EMA on voreloxin program

June 3, 2010

EMA considers postapproval commitment fulfilled for Ceplene/IL-2 in AML

June 2, 2010

Wyeth Europa notifies EMA of withdrawal of MAA for Brilence

June 1, 2010

FDA and EMA approve reanalysis of images from phase III RG-1068 trial

May 31, 2010

Prolia obtains marketing authorization in E.U.

May 31, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...